Adaptive Randomization for Multiarm Comparative Clinical Trials Based on Joint Efficacy/Toxicity Outcomes
From MaRDI portal
Publication:3183237
Recommendations
- Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity
- Efficient adaptive randomization and stopping rules in multi-arm clinical trials for testing a new treatment
- Comparison of designs for adaptive treatment strategies: Baseline vs. adaptive randomization
- Optimal and lead-in adaptive allocation for binary outcomes: a comparison of Bayesian methods
- A randomized play-the-winner design for multi-arm clinical trials
Cites work
- A Continuous Bivariate Exponential Extension
- Adaptive decision making in a lymphocyte infusion trial
- Bivariate Survival Models Induced by Frailties
- Monitoring the rates of composite events with censored data in phase II clinical trials
- Multivariate Generalizations of the Proportional Hazards Model
- Response-Adaptive Randomization for Survival Trials: The Parametric Approach
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
- The Calculation of Posterior Distributions by Data Augmentation
Cited in
(1)
This page was built for publication: Adaptive Randomization for Multiarm Comparative Clinical Trials Based on Joint Efficacy/Toxicity Outcomes
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3183237)